The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to negotiations that could either lead to a new alliance or Arvinas to seek a new ...

Drugmaker Viatris beat Wall Street estimates for second-quarter profit and revenue on Thursday, helped by demand for its products in China, sending its shares up nearly 5% in early trading.

Last December, the company raised its quarterly payout for the 16th consecutive year. The dividend yield investors could ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...